UK TEL: +44 (0) 1234 780020 | USA TEL: +1 888 381 6870
According to the World Health Organization there are officially 20 Neglected Tropical Diseases (NTDs). Many of these are preventable with the correct intervention, with some, such as lymphatic filariasis, targeted for elimination. Despite their prevalence, NTDs have ranked low in global health agendas. Diagnostics for these diseases have been especially neglected, given the lack of commercial return in this sector. The WHO's 2030 Roadmap for Neglected Tropical Diseases clearly identifies lack of diagnostics as one of the major barriers to achieving the control or elimination goals the world has agreed upon. As part of its philanthropic mission, Global Access Diagnostics (GADx) is fully committed to the development of diagnostic tests to help control or eliminate these preventable diseases. We are a proud signatory to the Kigali Declaration on NTDs, supporting countries in their fight to end the neglect.
An innovative dual rapid diagnostic test that detects viral antigens and antibodies (IgM and IgG), which delivers superior results. This was the first product manufactured by diaTROPIX, a department of the Institut Pasteur of Dakar and GADx’s Senegalese partner.
Developed in partnership with FINDdx, a global health non-profit, this rapid test detects antigen via a blood sample. This method is more efficient than the existing gold standard tests that rely on stool and urine samples.
A rapid test that will help support the mapping and elimination of River Blindness. The method of testing is non-invasive in contrast with skin snip biopsy, which is currently the primary method of diagnosing Onchocerciasis.
A rapid test for the differentiation of P. falciparum and P. vivax malaria. This test detects malaria LDH and its ultra-sensitive detection will support malaria elimination efforts.
An immunochromatographic rapid test, using the recombinant antigen K39, to detect the presence of antibodies against Leishmania spp.
The rapid test can be conducted with whole blood (capillary) or with serum; the result is obtained within 20 minutes with whole blood and 10 minutes with serum
NTD programmes have to understand where the disease is to be able to implement preventative measures. With better diagnostics, communities will receive the right support.
Ministries of Health and donors spend around $300 million annually on preventing the five most common NTDs. Better diagnostics are crucial to making sure the programmes they implement target the right places, stop treatments at the right time and can detect recurrences.
NTDs benefit from the largest drug donation
programme in history. But those drugs may not be effectively used if programmes don't know which communities need them most. Our diagnostics aim to help programmes get donated medicines to where they are most needed.
If you see a product that meets your goals to improve the health of your customers, just contact us using the form below.
Whether it is a product in our development phase or a new product idea, we will help you explore options and outline how we can serve you best.
We are flexible in meeting your needs, whether it’s through licensing, direct sales, a distribution or a development partnership, we can suit your business needs in a seamless process from start to finish.
Get in touch to find out how we can help meet your rapid, point-of-care diagnostics needs.
Mologic Ltd trading as Global Access Diagnostics. Company registered in England and Wales .Company Registration No. 4784437 | All Rights Reserved